Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar KimLanners (< 20) Submitted: 11/15/2011 7:18:24 PM : Underperform Start Price: $1.68 GERN Score: +21.32

down

Featured Broker Partners


Advertisement